

Strategic development towards long-term growth...

About the stock: Solar Industries (SIL) is one of the largest domestic manufacturers of bulk and cartridge explosives, detonators, detonating cords and components which find applications in the mining, infrastructure, construction industries

- Product range includes packaged explosives, initiating systems, UAS drones, ammunitions, military explosives, rocket integration, bombs etc.

Investment Rationale:

- Omnia acquisition strengthens Solar's global explosives platform and opens a new leg of growth:** The proposed US\$1.35 billion (~₹12,951 crore) acquisition of Omnia materially strengthens Solar's international explosives franchise, with combined annual revenue expected at ₹31,000-32,000 crore post-acquisition. The acquisition brings BME's (blasting & metallurgy solutions segment) established presence in bulk emulsions, packaged explosives, initiation systems etc. across Africa and other global markets, while Omnia's nitric acid and ammonium nitrate capabilities provide greater raw-material security and vertical integration. Solar can also leverage BME's distribution network to expand its packaged explosives and initiating systems, while Problast's down-the-hole capabilities add further synergies. With distribution reach increasing from ~90 to ~110 countries and manufacturing presence from 11 to 25+ countries, we believe the transaction as an extension of Solar's existing global expansion strategy rather than a standalone diversification. The company is also benefiting from a favourable tailwind in global explosives & high-energy materials industry, with shortages of these key materials supporting higher realisations across both domestic and international markets
- Defence remains the key growth engine, now complemented by global scale-up:** Solar's defence business continues to scale up, with management reiterating that the ₹12,000+ crore defence capex programme remains on track and allocation towards defence will not decline. The company's expanding portfolio across UAVs, counter-drone systems, missiles and other advanced munitions, along with a strong defence order pipeline, provides visibility for sustained growth. Management expects Solar standalone revenue at ~₹14,000 crore in FY27 with 28-29% EBITDA margin. Importantly, the Omnia acquisition is not at the expense of defence investments, while the enlarged global footprint could also create additional avenues for exporting Solar's defence and explosives products.

Rating and Target Price:

- We have not factored in the Omnia's acquisition in our financials for FY27E and FY28E, as we wait for its completion post all the required approvals. Though the margins and EPS of SIL would dilute by some extent after the full consolidation in FY29E (due to lower margins of Omnia), we believe that this acquisition would generate sizable opportunities for SIL in global explosives market and would be a value-accretive deal in longer-term
- We maintain BUY on Solar Industries with target price of ₹ 23,200 (based on 70x P/E on FY28E EPS)




Particulars

Particular	Amount
Market Capitalisation (₹ Crore)	1,69,805
FY26 Gross Debt (₹ Crore)	1,468
FY26 Cash (₹ Crore)	595
EV (₹ Crore)	1,70,677
52 Week H/L (₹)	20400/ 11641
Equity Capital	18
Face Value	2

Shareholding pattern

	Sep-25	Dec-25	Mar-26	Jun-26
Promoter	67.9	67.9	67.9	67.9
FII	3.2	2.7	3.1	2.8
DII	6.5	6.5	6.1	7.0
Others	22.4	22.9	22.9	22.3

Price Chart



Key risks

- Dependent on govt. contracts
- High working capital requirements
- Availability of key raw materials

Research Analyst

Vijay Goel
vijay.goel@icicisecurities.com

Kush Bhandari
kush.bhandari@icicisecurities.com

Key Financial Summary

Key Financials (₹ Crore)	FY23	FY24	FY25	FY26	3-year CAGR (FY23-26)	FY27E	FY28E	2-year CAGR (FY26-28E)
Revenues	6,922.5	6,069.5	7,540.2	9,837.7	12.4	14,038.4	17,037.6	31.6
EBITDA	1,288.9	1,369.2	1,960.3	2,621.8	26.7	3,835.5	4,663.4	33.4
EBITDA margin (%)	18.6	22.6	26.0	26.7		27.3	27.4	
Net Profit	757.5	835.6	1,209.4	1,677.6	30.3	2,445.2	3,007.4	33.9
EPS (Rs)	83.7	92.3	133.7	185.4		270.2	332.3	
P/E (x)	224.2	203.2	140.4	101.2		69.4	56.5	
EV/EBITDA (x)	132.4	124.5	86.5	65.1		44.7	36.6	
RoCE (%)	29.1	26.7	27.6	27.4		32.7	33.1	
RoE (%)	29.0	25.3	27.4	25.6		30.3	27.4	

Source: Company, ICICI Direct Research

Acquisition concall highlights

- Company has signed definitive agreements to acquire 100% of Omnia Holdings, South Africa, through its wholly owned step-down subsidiary Solar SA Investments, for US\$1.35 billion; the transaction remains subject to regulatory, shareholder and other approvals.
- The acquisition is aimed at creating an integrated global platform across commercial explosives, blasting solutions and mining services, combining Solar's explosives and initiating systems with Omnia/BME's ammonium nitrate, bulk explosives, electronic detonators and blasting services.
- Omnia generated ~₹13,300 crore revenue last year, while management expects it to reach ₹15,000+ crore revenue by FY28. Solar, meanwhile, is expected to grow from ~₹14,000 crore revenue in FY27 to ~₹16,500 crore in FY28, implying consolidated revenue of ~₹31,000-32,000 crore in FY28.
- Management expects consolidated EBITDA of ₹6,800-7,000 crore in FY28, translating into an EBITDA margin of ~22-23%. Solar's FY27 revenue is expected at ~₹14,000 crore with 28-29% EBITDA margin, while Solar's FY28 standalone revenue of ~₹16,500 crore at ~29% margin would contribute ~₹4,800 crore EBITDA.
- The acquisition is expected to significantly strengthen Solar's presence in Africa, with management indicating African mining revenue could increase from ~US\$300 million currently to ~US\$900 million-1 billion after combining Solar and Omnia/BME operations
- Solar's distribution footprint is expected to increase from ~90 to >100 countries (~110), while its manufacturing presence could expand from 11 to 25+ countries, providing access to new markets including North America, Australia and Indonesia.
- Vertical integration is a key benefit, with Omnia's nitric acid and ammonium nitrate facilities strengthening raw-material security, while Solar's initiating systems and Problast's down-the-hole services can be cross-sold through BME's distribution network.
- BME currently operates at ~13-14% EBITDA margin, versus global explosives industry margins of ~18-19%; management sees meaningful scope for margin improvement through ammonium nitrate integration, initiating-system sales and Problast services.
- The acquisition will be funded through internal accruals and debt, with no equity dilution planned. Management expects consolidated debt to remain below 2x EBITDA, with EBITDA targeted at ₹6,800-7,000 crore by FY28.
- Solar intends to continue its defence capex programme of ~₹12,000 crore and management said capital allocation towards defence will not reduce following the acquisition.
- Omnia's agriculture business will be retained as a complementary technology-led crop nutrition, biological and aggrotech business; however, management currently has no plans to expand this business into India

Exhibit 1: Consolidated financial profile post Omnia acquisition (likely in FY29E) (₹ crore)

	Solar Industries	Omnia Holdings	Total Consolidated financials (post acquisition)
Revenue from Operations	20,445	15,500	35,945
EBITDA Margin	28%	13.00%	22%
EBITDA	5,725	2,015	7,740
PAT	3,680	930	4,610
PAT Margin	18%	6%	13%

Source: Company, ICICI Direct

Exhibit 2: Omnia Holding's product portfolio



Bulk emulsions

BME's bulk emulsions are high quality and reliable. We were the first explosives company to introduce cold emulsions into South African opencast mines.



Packaged explosives

BME's packaged products are manufactured in our world-class production facility.



Initiation systems

BME manufactures and supplies a range of initiating systems that are performance driven, reliable and cost efficient.



BME Metallurgy

BME Metallurgy delivers integrated metallurgical solutions and mining chemicals that help mining operations optimise



Surface and underground technology

AXOS™ was developed in-house by BME and is a fully programmable, accurate and easy-to-use electronic delay detonator system.



Equipment

BME has a variety of manufactured equipment that deliver the safest and most cost-effective blasting outcome.



Hydrogen peroxide emulsion

BME's partnership with Hypex Bio enables it to deliver a hydrogen peroxide emulsion that offers significant environmental benefits compared to ammonia nitrate explosives.

Source: Company, ICICI Direct

Financial summary

Exhibit 3: Profit and loss statement

₹ crore

(₹Crore)	FY25	FY26	FY27E	FY28E
Revenue	7,540	9,838	14,038	17,038
Growth YoY (%)	24.2	30.5	42.7	21.4
Raw Material Expenses	3,907	4,894	7,075	8,519
COGS	51.8	49.7	50.4	50.0
Employee Expenses	600	845	1,082	1,298
Other Expenses	1,073	1,477	2,046	2,557
Total Op. Expenditure	5,580	7,216	10,203	12,374
EBITDA	1,960	2,622	3,836	4,663
Growth YoY (%)	43.2	33.7	46.3	21.6
Interest	117	134	162	144
Other Income	71	128	79	99
PBDT	1,915	2,616	3,753	4,619
Depreciation	182	251	340	440
PBT after Excl. Items	1,739	2,365	3,413	4,179
Total Tax	451	629	908	1,112
PAT before MI	1,288	1,737	2,505	3,067
Minority Interest	78	59	60	60
PAT	1,209	1,678	2,445	3,007
Growth YoY (%)	44.7	38.7	45.8	23.0
EPS	134	185	270	332
Revenue	7,540	9,838	14,038	17,038

Source: Company, ICICI Direct Research

Exhibit 4: Cash flow statement

₹ crore

(₹Crore)	FY25	FY26	FY27E	FY28E
Profit after Tax	1,209	1,678	2,445	3,007
Add: Depreciation	182	251	340	440
Add: Interest Paid	117	134	162	144
Cash Flow before WC changes	1,507	2,062	2,947	3,591
(Inc.)/Decrease in inventory	(193)	(702)	(489)	(337)
(Inc.)/Decrease in debtors	(394)	(619)	(642)	(487)
(Inc.)/Decrease Loan & Advances	1	(2)	-	-
(Inc.)/Decrease in CA	(135)	(263)	(133)	(40)
Net Increase in Current Ass.	(720)	(1,585)	(1,264)	(864)
Net Increase in Current Liab.	588	233	870	387
Net CF from op. activities	1,375	710	2,553	3,115
(Pur.)/Sale of Fixed Ass.	(948)	(1,485)	(2,000)	(2,000)
Inc / (Dec) in Df. Tax Liability	21	53	-	-
Net CF from Investing Act.	(526)	(1,731)	(2,050)	(2,147)
Proc./(Repay) Secured Loan	(166)	529	300	(800)
Proc./(Repay) Unsec. Loan	-	-	-	-
(Payment) of Dividend	(90)	(100)	-	-
Interest Paid	(117)	(134)	(162)	(144)
Net CF from Financing Act.	(405)	884	(809)	(1,019)
Net Cash flow	444	(136)	(306)	(51)
Cash and Cash Eq. (beg.)	287	731	595	289
Cash and Cash Eq. (end)	731	595	289	238

Source: Company, ICICI Direct Research

Exhibit 5: Balance sheet

₹ crore

(₹ Crore)	FY25	FY26	FY27E	FY28E
Equity Capital	18.1	18.1	18.1	18.1
Reserve and Surplus	4,375	6,542	8,040	10,973
Total Sh. funds	4,393	6,560	8,058	10,991
Secured Loan	939	1,468	1,768	968
Unsecured Loan	-	-	-	-
Total Debt	939	1,468	1,768	968
Deferred Tax Liability	219	272	272	272
Total Liabilities	6,699	9,128	10,942	13,077
Gross Block	3,327	4,824	6,516	8,516
Acc. Depreciation	857	1,108	1,448	1,888
Net Block	2,470	3,716	5,068	6,628
Capital WIP	703	692	1,000	1,000
Total Fixed Assets	3,173	4,408	6,068	7,628
Inventory	1,040	1,742	2,231	2,567
Debtors	1,239	1,858	2,500	2,987
Loans and Advances	2	4	4	4
Other Current Assets	587	850	983	1,022
Cash	731	595	289	238
Total Current Assets	3,599	5,048	6,006	6,819
Creditors	887	917	1,346	1,634
Provisions	24	40	40	40
Total Cur. Liabilities	1,568	1,801	2,671	3,058
Net Current Assets	2,031	3,247	3,335	3,761
Total Assets	6,699	9,128	10,942	13,077

Source: Company, ICICI Direct Research

Exhibit 6: Key ratios

(Year-end March)	FY25	FY26	FY27E	FY28E
Per Share Data				
Reported EPS	133.7	185.4	270.2	332.3
Cash EPS	153.7	213.1	307.8	381.0
BV per share	485.4	724.9	890.5	1,214.6
Dividend per share	10.0	11.0	16.0	18.0
Cash Per Share	94.7	122.5	160.0	208.7
Operating Ratios (%)				
EBITDA Margin	26.0	26.7	27.3	27.4
EBIT / Net Sales	23.6	24.1	24.9	24.8
PAT / Net Sales	16.0	17.0	17.4	17.7
Inventory days	50.3	64.6	58.0	55.0
Debtor days	60.0	68.9	65.0	64.0
Creditor days	42.9	34.0	35.0	35.0
Return Ratios (%)				
RoE	27.4	25.6	30.3	27.4
RoCE	27.6	27.4	32.7	33.1
RoIC	39.3	32.2	36.6	36.1
Valuation Ratios (x)				
P/E	140.4	101.2	69.4	56.5
EV / EBITDA	86.5	65.1	44.7	36.6
EV / Net Sales	22.5	17.3	12.2	10.0
Market Cap / Sales	22.5	17.3	12.1	10.0
Price to Book Value	38.7	25.9	21.1	15.4
Solvency Ratios				
Debt / EBITDA	0.5	0.6	0.5	0.2
Debt / Equity	0.2	0.2	0.2	0.1
Current Ratio	3.0	4.6	4.1	3.9
Quick Ratio	1.9	2.8	2.5	2.4

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%

Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk,
ICICI Securities Limited,
Third Floor, Brillanto House,
Road No 13, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Vijay Goel, PGDBM, Kush Bhandari, MBA, Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stockbroker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stockbroker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Jeetu Jawrani Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report

SEBI Guidelines for Research Analyst (RA) requires all RAs to disclose terms and conditions pertaining to Research Services to all clients. Please go through the "Mandatory terms and conditions" and "[Most Important Terms and Conditions](#)".